SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs stronger-than-expected quarterly results and rapid growth in its AI-compute business, alongside plans for an aggressive expansion, fueled a bullish reaction and a sharp after-hours move. Traders are divided over whether the growth outlook justifies the valuation given heavy capital spending, while some also point to a potential Tesla merger as an additional, uncertain catalyst.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its sales outlook and gross-margin expectations on stronger AI-platform demand, driving a rally and renewed optimism about AI-server growth. Traders largely welcomed the update and debated potential short covering and the stocks valuation, while some remained cautious about whether the gains will hold and whether execution can be sustained.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares came under pressure after its earnings report paired a profit beat with a weaker fourth-quarter outlook and a lower advertising-revenue forecast. Traders focused on slowing growth and streaming competition, while some dip buyers argued the selloff was excessive given the companys continued profitability.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention on a sharp price rebound and a renewed breakout attempt, with traders linking the move to Robinhood Chain and other payroll/payment partnerships. Bullish posts point to expanding adoption, while skeptics say sustained usage, trading volume and token demand still need to confirm the thesis; the Robinhood-related catalyst is also discussed with some uncertainty.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron first flight has been pushed to 2027 after a manufacturing defect in its carbon-composite propellant dome, with replacement work underway. Traders remain divided: some question execution and the lack of a firmer schedule, while others view the selloff as an overreaction and are buying for the long term.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans quarterly results beat expectations, its 2026 outlook was raised, and its backlog reached a record, driving the sharp move higher. Traders are weighing the strong results against a pullback from the session high and whether buyers can sustain the gains.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel data in progressive MS, alongside long-term BRIUMVI and other clinical updates. Traders are positioning ahead of the readouts, with some optimistic about azer-cels potential and others stressing that its clinical impact remains uncertain; ongoing BRIUMVI growth provides a commercial backdrop.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale is under pressure after Barclays downgraded the stock, citing commercial execution risks and delays in securing a definitive TVAENTRA1 agreement for the proposed deployment. Traders debate whether the selloff overstates the risk: bears point to the lack of firm project commitments, while bulls cite AI-driven power demand and NuScales longer-term nuclear opportunity.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is drawing attention as it rises into its third-quarter earnings report, with traders focused on software growth, delayed-deal conversion and managements guidance after the prior quarters weakness. Bulls point to the recent momentum and call buying, while others worry about another earnings-driven selloff or a sell the news reaction.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

FAA certification of Boeings 737 MAX 10 is the dominant catalyst, with bulls viewing it as a step toward deliveries and cash generation while skeptics say approval alone may not move the stock. Traders largely focus on whether Boeing can ramp production and convert its backlog into actual deliveries.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million.
Aligos Therapeutics (NASDAQ:ALGS) sharesread more...

Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock

Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and China Breakthrough Therapy designation.read more...

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal 

Equity

The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.

Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical levels shape investor outlook.read more...

This Micro Cap Biotech Stock Is Tracking Its Biggest Intraday Gains In 11 Months – Here’s Why A China Deal Has Retail Buzzing

Aligos Therapeutics announced a licensing deal with Xiamen Amoytop Biotech to develop and commercialize its hepatitis B drug candidate in Greater China.

Aligos Therapeutics Earnings Report: Q4 Overview

A Peek at Aligos Therapeutics's Future Earnings

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% - Time to Sell?

Aligos Therapeutics (NASDAQ:ALGS) Trading Down 4.5% - Here's What Happened...

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Aligos Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Under the licensing deal signed earlier this year, Aligos granted Xiamen Amoytop Biotech exclusive rights to develop and sell its experimental hepatitis B treatment drug, pevifoscorvir sodium, in Greater China.</li><li>Under the deal, Aligos is eligible for up to $420 million in milestone payments tied to clinical, regulatory, and sales achievements.</li><li>Aligos Therapeutics had $54.9 million in cash, cash equivalents and short-term investments as of March 31, 2026.</li></ul> Shares of Aligos Therapeutics (ALGS) rose 21% in after-hours trading on Monday after the company announced it had received a $25-million upfront payment from its Chinese licensing partner.The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases. Aligos Therapeutics had only $54.9 million in cash, cash equivalents, and short-term investments as of March 31, 2026.<h2 class="st-heading-2">The Licensing Deal</h2>Under the licensing deal signed earlier this year, Aligos granted Xiamen Amoytop Biotech exclusive rights to develop and sell its experimental hepatitis B treatment, pevifoscorvir sodium, in Greater China. Aligos keeps full rights to the drug in the United States, Europe, Japan, South Korea, and all other markets.Under the deal, Aligos is eligible for up to $420 million in milestone payments tied to clinical, regulatory and sales achievements. It will also earn tiered royalties in the high single digits on net sales in the licensed region.The treatment has already received Breakthrough Therapy Designation from Chinese regulators, which can speed up the approval process. A joint steering committee between the two companies is now overseeing the program. As part of the broader collaboration, the partners also plan to start clinical testing in China of another Aligos drug candidate in the third quarter of this year.<h2 class="st-heading-2">How Did ALGS Retail Traders React?</h2>On Stocktwits, retail sentiment around ALGS stock jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user opined that the stock is highly undervalued.<stembedurl>https://www.stocktwits.com/saitek88/message/658388690</stembedurl>“Cash-in now, but the real read is whether this deal de-risks the story and adds validation for the asset. Market will watch follow-through on the platform, not just the headline,” another user wrote.<stembedurl>https://www.stocktwits.com/SmartCapitall/message/658384603</stembedurl><a href="https://stocktwits.com/symbol/ALGS">ALGS stock</a> has fallen by about 37% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivn-stock-drops-after-hours-on-potential-1.5-billion-offering/cZm1A9rR7lC">RIVN Stock Drops After-Hours On Potential $1.5B Offering Despite Upbeat Q2 Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Interactive Strength Inc. rose on Friday (Representative image: Getty Images)

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ALGS — This licensing deal caught my attention. Aligos gets $25M upfront and could receive up to $420M in milestones for its hepatitis B candidate in Greater China. Pretty meaningful economics for a company this size.

Trading Edge

$ALGS Things are looking better since my last post, but it's too early to say if the trend has actually changed since ALGS has such low volume and float, meaning even a little trading can swing the price a lot.

Whatever is driving the climb, it's exciting to see regardless.

$ALGS how we doing over here? Doing standard $ALGS things? Back to the $3S because…..why not. There’s this dark corner of the market where a bunch of stocks reside.  These stocks have the “nobody cares”  label on them.  The shares serve one purpose. Sell them to keep salaries paid. They are not intended to appreciate.  Once you come to grips with this, it all makes sense. Heard from the CEO in months?   Maybe his music career is starting to take off and he’s distracted?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALGS Aligos Therapeutics Inc

Fundamentals

Latest ALGS News